Skip to main content

FDA Pilot Program for Certain In Vitro Diagnostic Tests

The U.S. Food and Drug Administration (FDA) has announced a pilot program designed to improve oncology patient care by establishing minimum performance standards for in vitro diagnostic tests (IVDTs) used with a limited number of oncology drug products. An IVDT is a device that provides critical information for the safe and effective use of a therapeutic product. The FDA typically requires a companion diagnostic to receive marketing authorization concurrently with the approval of the corresponding therapeutic product. However, in cases where no satisfactory alternative treatment exists for a serious or life-threatening condition, the FDA may approve a therapeutic product even without a companion IVDT. Currently, laboratory developed tests (LDTs) are being used in such cases, and the FDA exercises enforcement discretion regarding these tests.



The pilot program aims to improve drug selection and patient care by establishing minimum performance characteristics for certain LDTs used in identifying patients for treatment with specific oncology drugs.

As a part of the pilot program, the FDA plans to recommend minimum analytical performance characteristics for certain tests used in oncology drug products. These recommendations are intended to establish a benchmark for test developers to design accurate and reliable tests for identifying patients for oncology treatment.

These performance characteristics would be based on the clinical validity established for the clinical trial assays (CTAs) used in the pivotal clinical trials supporting the approval of the drug products. The minimum performance characteristics would be recommended for other tests of the same type, and when these tests demonstrate the recommended performance through properly conducted validation studies, the FDA believes their clinical validity can be extrapolated.

Participation in the pilot program is open to drug product sponsors who meet specific criteria. These include the need for an IVDT to identify the intended patient population, the absence of satisfactory alternative treatments, and the substantial benefits outweighing the risks of approval without an FDA-authorized companion diagnostic.

Drug product sponsors interested in the pilot program should submit a Statement of Interest along with their IND, NDA, or BLA applications. The FDA will review the factors outlined in the document to determine acceptance into the program and provide written feedback. The FDA has provided templates on its website to facilitate the submission of performance characteristic and validation information for the CTAs used in pivotal clinical trials. The minimum recommended performance characteristics for IVDTs associated with approved drug products will also be publicly available on the FDA's website.

The FDA intends to update the guidance based on the initial phase of the pilot program and plans to expand the program to evaluate additional sponsors for acceptance. This pilot program aims to enhance oncology patient care by establishing standardized performance criteria for diagnostic tests used in conjunction with oncology drug products.

Download the full FDA guidance document here, and read the Federal Register notice here.

Comments

Post a Comment

Popular posts from this blog

The Future of Liquid Biopsies: Endless Possibilities for Cancer Testing

Liquid biopsies are poised to disrupt cancer testing as we know it. These novel blood tests analyze circulating tumor DNA (ctDNA) and other molecules released by cancer cells, providing a non-invasive option for detection, diagnosis, and monitoring. The promise of liquid biopsies has generated tremendous excitement, along with over $1 billion in investments and acquisitions in recent years. But how close are we to realizing their full potential?  A recent review article sounds a note of caution amidst the hype. While liquid biopsies show ability to detect cancer, evidence that they improve patient outcomes is still lacking. Randomized trials with survival endpoints are needed to prove clinical utility. However, this provides the perfect opportunity for innovative diagnostics companies. Rather than dampening enthusiasm, these evidence gaps highlight major growth possibilities if companies can demonstrate real-world value.   We envision liquid biopsies transforming oncology...
Post a Comment
Read more

The Problem of Limited-Supply Agreements for Medicare Price Negotiation

A recent JAMA Viewpoint article discusses how limited-supply agreements between brand name and generic drug makers could impact Medicare price negotiation under the Inflation Reduction Act (IRA). These agreements allow brand manufacturers to maintain some market exclusivity by limiting the supply of generic competitors. The article suggests these deals may increase as the Centers for Medicare and Medicaid Services (CMS) implements the IRA's price negotiation provisions. From a business perspective, it's understandable why brand manufacturers might find limited-supply agreements preferable to having their drugs subject to Medicare negotiation. Maintaining even partial exclusivity is likely better for revenue than triggering government-dictated price reductions. However, policymakers and patients are increasingly concerned that these deals keep prices high despite generic availability. The use of limited supply agreements could also produce unintended consequences.  Balancing som...
Post a Comment
Read more

FDA Green Light Inches Genetic Screening Forward

The FDA recently granted authorization for the first multi-gene test for assessing hereditary cancer risk, marking a significant advancement in genetic screening capabilities. Developed by Invitae Corporation, the Invitae Common Hereditary Cancers Panel analyzes variants in 47 genes associated with increased cancer risk. Using next-generation sequencing on DNA from blood samples, the test looks at BRCA1 and BRCA2 variants linked to breast and ovarian cancer, as well as other cancer-related genes.  (image source: Adobe Stock Images) The FDA’s approval provides a regulatory framework giving labs a clearer roadmap for developing similar multi-gene panels. With an authorized model in place, labs can proceed more confidently in navigating FDA submissions. Specifically, the de novo classification created for Invitae’s test allows future lab-developed panels to gain regulatory clearance through the expedited 510(k) pathway by demonstrating substantial equivalence. This streamlined validat...
Post a Comment
Read more